Sign inJoin waitlistJoin the waitlist

Elaine Shum

Director, Cancer Screening Programs · NYU Grossman School of Medicine

Credentials: · ·

History

NYU Grossman School of Medicine
Present
NYU Grossman Long Island School of Medicine · NYU Grossman School of Medicine
Present

Hematology and Medical Oncology
Montefiore Einstein
2014–2017
SAINT LUKES ROOSEVELT HOSPITAL
2011–2014
Renaissance School of Medicine at Stony Brook University
2007–2011

Research

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Journal of Clinical Oncology · 2025 · 117 citations
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
Clinical Cancer Research · 2021 · 108 citations
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation
Cell · 2021 · 98 citations

Balazs Halmos
8 papers
Haiying Cheng
7 papers
Joshua Sabari
7 papers
Pasi Jänne
5 papers
Vamsi Velcheti
5 papers
Xiuning Le
5 papers
Jacob Sands
4 papers
John Heymach
4 papers
Andre Moreira
3 papers
George Blumenschein
3 papers
Jonathan Riess
3 papers
Kwok-Kin Wong
3 papers

Clinical trials

Female Asian Nonsmoker Screening Study
Principal investigator · Active not recruiting
NYU Langone Health
2021–2035
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Site PI · Recruiting · Phase 3
Nuvalent Inc.
2025–2029
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
Site PI · Unknown
Lung Cancer Mutation Consortium
2022–2026
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Site PI · Recruiting · Phase 1, Phase 2
Nuvalent Inc.
2022–2028